Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
PELOBIOTECH GmbH is happy to announce organizing the first conference "Advancements in Animal-Free Research and Translat…
Latest survey on traffic visibility for ZTNA shows over half of ZTNA vendors expect severe security implications from…
For one week, the capital of Gran Canaria, Las Palmas, was transformed into a laboratory for "Sustainable Life". An inte…
Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million…
Publication in Biotechnology Journal A broadly designed comparative study conducted by researchers from Karolinska Inst…
Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it wi…
MagnetOs™ Granules becomes the third product in the MagnetOs portfolio to receive FDA clearance to market for inter…
Rheinmetall Defence UK has been working hard to improve support and opportunities to early careers in Science, Technolog…
Registration is now open for Emerson Exchange Europe, Middle East and Africa (EMEA) 2024, which will take place at the C…